Cyclic Nucleotide Phosphodiesterases, Type 3
"Cyclic Nucleotide Phosphodiesterases, Type 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is inhibited by the binding of CYCLIC GMP to an allosteric domain found on the enzyme and through phosphorylation by regulatory kinases such as PROTEIN KINASE A and PROTEIN KINASE B. The two members of this family are referred to as type 3A, and type 3B, and are each product of a distinct gene. In addition multiple enzyme variants of each subtype can be produced due to multiple alternative mRNA splicing.
MeSH Number(s)
D08.811.277.352.640.150.300
D12.644.360.008.300
D12.776.476.008.300
Concept/Terms
Cyclic Nucleotide Phosphodiesterases, Type 3- Cyclic Nucleotide Phosphodiesterases, Type 3
- Phosphodiesterase III
- Cyclic Nucleotide Phosphodiesterase PDE3 Family
- cGMP-Inhibited Cyclic Nucleotide Phosphodiesterase
- cGMP Inhibited Cyclic Nucleotide Phosphodiesterase
- cGMP-Inhibited Phosphodiesterase
- Phosphodiesterase, cGMP-Inhibited
- cGMP Inhibited Phosphodiesterase
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 3".
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 3".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 3" by people in Harvard Catalyst Profiles by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 3" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2009 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2019 | 1 | 1 | 2 |
2020 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 3" by people in Profiles.
-
Rare and low-frequency exonic variants and gene-by-smoking interactions in pulmonary function. Sci Rep. 2021 09 29; 11(1):19365.
-
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Commun. 2021 07 16; 12(1):4375.
-
Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 03 13; 295(11):3431-3446.
-
Influence of Genetic Variation in PDE3A on Endothelial Function and Stroke. Hypertension. 2020 02; 75(2):365-371.
-
Nanoscale Surveillance of the Brain by Microglia via cAMP-Regulated Filopodia. Cell Rep. 2019 06 04; 27(10):2895-2908.e4.
-
PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Sci Rep. 2017 05 15; 7(1):1917.
-
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016 Feb; 12(2):102-8.
-
Clinical effects of phosphodiesterase 3A mutations in inherited hypertension with brachydactyly. Hypertension. 2015 Oct; 66(4):800-8.
-
Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised ß-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. Cell Stem Cell. 2015 Jul 02; 17(1):89-100.
-
PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet. 2015 Jun; 47(6):647-53.